Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Studie naar oestrogeensuppressie bij postmenopauzale borstkanker laat veel vragen onbeantwoord
okt 2024 | Borstkanker